Emyria (ASX:EMD), a leader in the development of innovative mental health treatments, has launched a targeted clinical workforce recruitment campaign in New South Wales.
The move marks the commencement of the company's fourth state-based clinical operation, targeting Australia's largest addressable patient population.
The campaign specifically seeks to hire psychiatrists and therapists to meet a surging demand for mental health services in the state.
Recent data highlights a critical need, with psychological injury claims in New South Wales rising by 64% since 2019-20.
The NSW Police alone incurred approximately $1.75 billion in related costs over the five years leading to June 2024.
The expansion leverages Emyria’s established national foundation, which already comprises a network of over 90 trained therapists operating across Western Australia, Queensland, and Victoria.
By establishing a physical presence in New South Wales, the company aims to accelerate its delivery of evidence-based interventions to frontline workers and the broader community.
The domestic growth aligns with a broader global shift towards psychedelic and next-generation mental health therapies.
As the sector nears a commercial inflection point—characterised by late-stage Phase 3 trials and major international acquisitions, such as Otsuka Pharmaceutical's US$1.23 billion purchase of Transcend Therapeutics—Emyria is positioning its payer-funded, clinical model to lead the transition.
At the time of reporting, Emyria's share price was $0.052.